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Dr Peter Gloviczki (Rochester, Minn). The orthopedic sur-
geons frequently send patients to us to remove varicose veins
because they are worried that those patients will develop deep vein
thrombosis. In the Olmsted County epidemiology study, John
Heit from the Mayo Clinic found that in young patients, varicosity
was a predictor of deep vein thrombosis. So my question to you,
did you look at this risk factor, and in any of the surgical groups was
varicosity a risk factor of deep vein thrombosis?
Dr Peter Henke. In this series, certainly, varicose vein exci-
sion is done in the VA system, but it was not included in this patient
data set. So the simple answer is I’m not sure if this is a risk factor
for postoperative VTE.
Dr Jan Brunkwall (Bonn, Germany). I was a little bit sur-
prised about your message that diabetes mellitus and dialysis
should be protective against thromboembolism. Because in previ-
ous studies, when we investigated renal transplant patients, espe-
cially the diabetics were the ones that had an increased risk of
getting a thromboembolism afterwards. Do you have any explana-
tion for that?
Dr Henke. Not right offhand. I think that patients who are
undergoing hemodialysis may get some protection from the hep-
arin that’s used during their dialysis run. They also have a func-
tional antiplatelet effect from their often-elevated BUN, so that
may be the explanation there. With diabetes, it may be that they
have a relative inactivity of their leukocytes, and thus this may
decrease a potential proinflammatory component to thrombogen-diabetes was protective in mortality. And we know diabetics long
term have higher chances of death than nondiabetics. So it may be
a statistical aberration as well.
Dr Michael Maxwell (Mesa, Ariz). Did you distinguish be-
tween different types of DVT, for example, popliteal DVT versus
iliofemoral thrombus? Did the two groups differ in their results?
Dr Henke. The definitions with the NSQIP do not differen-
tiate between those two types of DVT.
Dr Alan Lumsden (Houston, Tex). Clearly, the strength of
the NSQIP database is the size and the scope of the hospitals that
are involved. The Achilles heel, of course, is the accuracy of the
diagnosis of venous thromboembolic disease. This is largely a
database of discharge diagnosis with 30-day follow-up.
Dr Henke. That’s correct, but it is not an administrative data
set. The VTE diagnosis is confirmed by an ultrasound report of
DVT, or with pulmonary embolism, either by pulmonary angiog-
raphy or two or more segment VQ mismatch by trained nurse
reviewers.
Dr Lumsden. Clearly, there are a variety of patients and a
variety of different centers. Do you have any sense of how the
diagnosis was established rather than just basically how the ICD-9
codes are being reported?
DrHenke.Again, with theNSQIP database, theDVT and PE
are prospectively acquired after the surgical procedure and do not
rely on ICD-9 codes.
Dr Lumsden. One last question. If you get an aortic aneu-
rysm, you’re in the hospital for 7 days. If you get a laparoscopic
cholecystectomy, you may be discharged the following day. Does
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hospitalization, independent of the magnitude of the procedure?
In other words, are you just more likely to get diagnosed with a
symptomatic DVT if you happen to be in the hospital at the time?
Dr Henke. Good question. Again, we did not specifically
look at length of stay versus the risk of VTE. Certainly if you
have complications such as pneumonia, UTI, myocardial infarc-
tion, your length of stay also increases, and it may be hiddenso if a VTE occurs as an outpatient, they are almost always
captured.
Dr Anton Sidawy (Washington, DC). As a follow-up to Dr.
Lumsden’s question, I wonder whether this manuscript’s title
should be changed to include the word “symptomatic” to qualify
DVT, because obviously you are not screening asymptomatic
patients in this study; the diagnosis is made on symptomatic
patients.within those variables. But, all patients are followed for 30 days, Dr Henke. Very good point. I agree.
